Inocras Fuels U.S. Precision Oncology Push with $31M Capital Infusion
August 5, 2026, 3:36 pm
Inocras, a San Diego bioinformatics leader, secured $31M in Series B-3 financing, raising its total capital to $100M. This investment fuels rapid U.S. expansion of its CLIA/CAP-certified whole-genome sequencing (WGS) and automated analytics. The platform, featuring CancerVision™ for comprehensive tumor profiling and MRDVision™ for ultra-sensitive molecular residual disease detection, revolutionizes precision oncology. It moves beyond narrow gene panel limitations. Proven across 100+ Asian cancer centers and supported by research collaborations with institutions like the Broad Institute, this funding marks a pivotal step in advanced cancer diagnostics.
Inocras secures substantial new funding. The San Diego-based bioinformatics company closed an oversubscribed $31 million Series B-3 financing round. This latest capital infusion boosts its total funding to approximately $100 million. Major investors backed the round. NDS Corporation and Aimed Bio Inc. provided strategic support. New participants included IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities, and Shinhan Securities. Other contributors like DSC Investment and Dunamu & Partners also joined. This significant investment targets a clear objective: robust U.S. expansion.
The funds will propel Inocras's CLIA/CAP-certified whole-genome sequencing (WGS) infrastructure into American markets. Its automated analytics platform will follow. This marks a strategic transfer of clinical models. These models already thrive across numerous Asian healthcare systems. Inocras plans to build out its operational, commercial, and laboratory presence throughout the United States. This expansion positions Inocras as a key player in the burgeoning U.S. precision oncology landscape.
Precision oncology faces persistent challenges. Traditional next-generation sequencing (NGS) panels offer limited views. They often miss critical genomic information. These panels focus on common coding mutations. They frequently overlook complex structural variants. Non-coding driver alterations also go undetected. Broader mutational signatures across the entire cancer genome remain hidden. The analytical ceiling of narrow gene panels creates operational hurdles. Comprehensive whole-genome interpretation is the future. Health systems demand automated bioinformatics pipelines. These pipelines must translate vast genomic data. They must deliver clinically actionable decisions rapidly. Patient treatment cannot suffer delays.
Inocras’s proprietary suite directly addresses these limitations. The platform integrates high-depth sequencing with automated interpretation algorithms. This streamlines clinical decision support. Two flagship products lead this charge: CancerVision™ and MRDVision™.
CancerVision™ offers comprehensive tumor profiling. It analyzes paired somatic and germline whole-genome data. This identifies single-nucleotide variants (SNVs). It detects indels and copy-number alterations (CNAs). Complex structural variants (SVs) are also captured. Non-coding alterations are included. CancerVision™ also measures crucial biomarkers. These include tumor mutational burden (TMB) and homologous recombination deficiency (HRD). This provides a holistic view of the cancer genome.
MRDVision™ tackles molecular residual disease (MRD) tracking. It uses a whole-genome, panel-free circulating tumor DNA (ctDNA) model. This achieves ultra-sensitive detection. Its limits of detection reach down to 1 part per million (ppm). Early and accurate MRD detection is critical. It informs treatment decisions. It monitors recurrence. This capability represents a significant leap forward in post-treatment cancer management.
Inocras boasts a demonstrated regional footprint. Its technology enjoys extensive clinical adoption across Asia. Over 100 Asian cancer institutions utilize its platform. Approximately 30 hospitals in South Korea actively partner with Inocras. The company also established a major commercial hub in Hong Kong. This proven track record provides a strong foundation. It validates the technology's efficacy and clinical utility.
The company further strengthens its credibility through large-scale population validation. Inocras collaborates with Broad Institute researchers. They analyze thousands of The Cancer Genome Atlas (TCGA) cancer cases. This collaboration aims to establish standardized whole-genome curation benchmarks. Such partnerships underscore Inocras's commitment to scientific rigor. They ensure its technology meets the highest standards.
The expansion into U.S. hospital networks marks a critical juncture. Inocras's CLIA/CAP-certified footprint ensures regulatory compliance. It guarantees high-quality laboratory standards. This whole-genome platform establishes a clear operational benchmark. It demonstrates how high-depth data automation will drive the future of precision oncology. Genomic insights will become more accessible. Clinical workflows will become more efficient. Patient care will improve.
Inocras offers a significant advantage for pharmaceutical companies and research institutions. Its platform accelerates discovery. It enhances diagnostics. Curated and actionable insights are delivered at scale. This facilitates new treatment development. It refines existing therapies. The impact extends beyond diagnostics. It contributes to broader advancements in cancer research.
The shift towards whole-genome interpretation is undeniable. Inocras is at the forefront of this paradigm change. Its robust funding, proven technology, and strategic expansion position it strongly. The company aims to make a real-world impact. It improves patient care through advanced genomic understanding. The future of precision health relies on such innovation. Inocras delivers it now.
Inocras secures substantial new funding. The San Diego-based bioinformatics company closed an oversubscribed $31 million Series B-3 financing round. This latest capital infusion boosts its total funding to approximately $100 million. Major investors backed the round. NDS Corporation and Aimed Bio Inc. provided strategic support. New participants included IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities, and Shinhan Securities. Other contributors like DSC Investment and Dunamu & Partners also joined. This significant investment targets a clear objective: robust U.S. expansion.
The funds will propel Inocras's CLIA/CAP-certified whole-genome sequencing (WGS) infrastructure into American markets. Its automated analytics platform will follow. This marks a strategic transfer of clinical models. These models already thrive across numerous Asian healthcare systems. Inocras plans to build out its operational, commercial, and laboratory presence throughout the United States. This expansion positions Inocras as a key player in the burgeoning U.S. precision oncology landscape.
Precision oncology faces persistent challenges. Traditional next-generation sequencing (NGS) panels offer limited views. They often miss critical genomic information. These panels focus on common coding mutations. They frequently overlook complex structural variants. Non-coding driver alterations also go undetected. Broader mutational signatures across the entire cancer genome remain hidden. The analytical ceiling of narrow gene panels creates operational hurdles. Comprehensive whole-genome interpretation is the future. Health systems demand automated bioinformatics pipelines. These pipelines must translate vast genomic data. They must deliver clinically actionable decisions rapidly. Patient treatment cannot suffer delays.
Inocras’s proprietary suite directly addresses these limitations. The platform integrates high-depth sequencing with automated interpretation algorithms. This streamlines clinical decision support. Two flagship products lead this charge: CancerVision™ and MRDVision™.
CancerVision™ offers comprehensive tumor profiling. It analyzes paired somatic and germline whole-genome data. This identifies single-nucleotide variants (SNVs). It detects indels and copy-number alterations (CNAs). Complex structural variants (SVs) are also captured. Non-coding alterations are included. CancerVision™ also measures crucial biomarkers. These include tumor mutational burden (TMB) and homologous recombination deficiency (HRD). This provides a holistic view of the cancer genome.
MRDVision™ tackles molecular residual disease (MRD) tracking. It uses a whole-genome, panel-free circulating tumor DNA (ctDNA) model. This achieves ultra-sensitive detection. Its limits of detection reach down to 1 part per million (ppm). Early and accurate MRD detection is critical. It informs treatment decisions. It monitors recurrence. This capability represents a significant leap forward in post-treatment cancer management.
Inocras boasts a demonstrated regional footprint. Its technology enjoys extensive clinical adoption across Asia. Over 100 Asian cancer institutions utilize its platform. Approximately 30 hospitals in South Korea actively partner with Inocras. The company also established a major commercial hub in Hong Kong. This proven track record provides a strong foundation. It validates the technology's efficacy and clinical utility.
The company further strengthens its credibility through large-scale population validation. Inocras collaborates with Broad Institute researchers. They analyze thousands of The Cancer Genome Atlas (TCGA) cancer cases. This collaboration aims to establish standardized whole-genome curation benchmarks. Such partnerships underscore Inocras's commitment to scientific rigor. They ensure its technology meets the highest standards.
The expansion into U.S. hospital networks marks a critical juncture. Inocras's CLIA/CAP-certified footprint ensures regulatory compliance. It guarantees high-quality laboratory standards. This whole-genome platform establishes a clear operational benchmark. It demonstrates how high-depth data automation will drive the future of precision oncology. Genomic insights will become more accessible. Clinical workflows will become more efficient. Patient care will improve.
Inocras offers a significant advantage for pharmaceutical companies and research institutions. Its platform accelerates discovery. It enhances diagnostics. Curated and actionable insights are delivered at scale. This facilitates new treatment development. It refines existing therapies. The impact extends beyond diagnostics. It contributes to broader advancements in cancer research.
The shift towards whole-genome interpretation is undeniable. Inocras is at the forefront of this paradigm change. Its robust funding, proven technology, and strategic expansion position it strongly. The company aims to make a real-world impact. It improves patient care through advanced genomic understanding. The future of precision health relies on such innovation. Inocras delivers it now.